Michael Amatangelo
YOU?
Author Swipe
View article: Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study
Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study Open
Introduction: Mezigdomide (MEZI) is an oral CELMoD™ agent that induces rapid and potent degradation of lkaros and Aiolos. Reduction in these transcription factors results in direct tumoricidal and immunomodulatory effects in multiple myelo…
View article: Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results
Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results Open
Introduction CAR T and bispecific antibody treatment for relapsed/refractory multiple myeloma (RRMM) show promising clinical activity, but most patients (pts) relapse. Emerging clinical data indicate that serial and/or prolonged T-cell–red…
View article: EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma Open
Multiple myeloma (MM) is a plasma cell neoplasm that stems from the malignant transformation of clonal plasma cells. It is characterized by multiple periods of remission and relapse requiring multiple lines of therapy, with response to tre…
View article: Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial
Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial Open
Introduction: Iberdomide (IBER) is a novel, oral CELMoD™ agent that induces ubiquitination and degradation of the hematopoietic transcription factors Aiolos and Ikaros. IBER binds cereblon (CRBN) with unique interactions and > 20-fold h…
View article: Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma
Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma Open
Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development in multiple myeloma (MM). The analysis of biomarker samples from relapsed/refractory patients enrolled in CC-220-MM-001 (ClinicalTrials.gov: NCT02…
View article: P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: MEZI, a novel oral cereblon E3 ligase modulator (CELMoD™) with enhanced tumoricidal and immune-stimulatory effects compared with IMiD® agents, induces maximal Ikar…
View article: Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma Open
Supplementary Methods and Data
View article: Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma Open
Purpose:Addition of daratumumab to pomalidomide and low-dose dexamethasone (LoDEX) is a safe and effective combination for relapsed/refractory multiple myeloma treatment. We sought to better understand immune combinational benefit of pomal…
View article: Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma Open
Purpose:Addition of daratumumab to pomalidomide and low-dose dexamethasone (LoDEX) is a safe and effective combination for relapsed/refractory multiple myeloma treatment. We sought to better understand immune combinational benefit of pomal…
View article: Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma Open
Supplementary Methods and Data
View article: P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL Open
Background: Iberdomide (IBER), a novel cereblon E3 ligase modulator (CELMoD®) compound, induces ubiquitination and proteasome-dependent degradation of Ikaros and Aiolos proteins, resulting in tumoricidal and immunomodulatory activity in mu…
View article: Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Open
Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs®) lenalidomide (LE…
View article: PF559 IBERDOMIDE (CC‐220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE‐DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT
PF559 IBERDOMIDE (CC‐220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE‐DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT Open
Background: Iberdomide (IBER) is a novel cereblon (CRBN) E3 ligase modulatory compound (CELMoD) that is being investigated as monotherapy, in combination with dexamethasone (DEX), and in combination with DEX and daratumumab or bortezomib i…
View article: Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib Open
Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective s…
View article: EXTH-34. COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
EXTH-34. COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO Open
Mutations in isocitrate dehydrogenase (IDH) 1 or 2 occur in >70% of diffuse low-grade gliomas (LGG). IDH1/2 mutations result in accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), which facilitates tumorigenesis through DNA hyper…
View article: Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Open
Key Points Enasidenib inhibits mIDH2, leading to leukemic cell differentiation with emergence of functional mIDH2 neutrophils in rrAML patients. RAS pathway mutations and increased mutational burden overall are associated with a decreased …
View article: Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts
Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts Open
Fibroblasts secrete and organize extracellular matrix (ECM), which provides structural support for their adhesion, migration, and tissue organization, besides regulating cellular functions such as growth and survival. Cell‐to‐matrix intera…